{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:37:47Z","timestamp":1792629467688,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"Summary<\/jats:title>\n \n The CAR\u2010HEMATOTOX model has been shown to help identify patients with relapsed\/refractory (R\/R) large B\u2010cell lymphoma (LBCL) at heightened risk of severe neutropenia, serious infection and worse clinical outcomes after chimeric antigen receptor T\u2010cell (CAR\u2010T) therapy. We evaluated whether CAR\u2010HEMATOTOX scores had prognostic value in patients with R\/R follicular lymphoma (FL) or diffuse large B\u2010cell lymphoma (DLBCL) treated with odronextamab (cluster of differentiation [CD]20\u2009\u00d7\u2009CD3 bispecific antibody) in the ELM\u20101 (NCT02290951) and ELM\u20102 (NCT03888105) studies. Patients were retrospectively stratified by baseline CAR\u2010HEMATOTOX score: CAR\u2010HEMATOTOX score low (HT\n low<\/jats:sup>\n [0\u20131]; FL,\n n<\/jats:italic>\n \u2009=\u2009115, DLBCL,\n n<\/jats:italic>\n \u2009=\u200992) or CAR\u2010HEMATOTOX score high (HT\n high<\/jats:sup>\n [\u22652]; FL,\n n<\/jats:italic>\n \u2009=\u200924, DLBCL,\n n<\/jats:italic>\n \u2009=\u200998). The incidence of grade \u22652 cytokine release syndrome within the first 30 treatment days, and rates of grade \u22653 infection and delayed neutrophil recovery within the first 90 treatment days, were numerically higher in HT\n high<\/jats:sup>\n versus HT\n low<\/jats:sup>\n patients. In patients with HT\n high<\/jats:sup>\n versus HT\n low<\/jats:sup>\n scores, progression\u2010free survival (PFS) was significantly poorer in DLBCL (2.6 vs. 9.6\u2009months [\n p<\/jats:italic>\n \u2009<\u20090.0001]), and overall survival (OS) was significantly worse in FL and DLBCL (FL, 26.5\u2009months vs. not reached [\n p<\/jats:italic>\n \u2009=\u20090.030]; DLBCL, 4.8 vs. 17.2\u2009months [\n p<\/jats:italic>\n \u2009<\u20090.0001]). These results suggest that the CAR\u2010HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.\n <\/jats:p>","DOI":"10.1111\/bjh.70869","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:37:51Z","timestamp":1792625871000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR<\/scp>\n \u2010\n HEMATOTOX<\/scp>\n score to predict risk of poor outcomes with odronextamab in heavily pretreated B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"first","affiliation":[{"name":"Division of Blood Disorders Rutgers Cancer Institute New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-4111","authenticated-orcid":false,"given":"David","family":"Tucker","sequence":"additional","affiliation":[{"name":"Haematology Department Royal Cornwall Hospital Truro UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3867-990X","authenticated-orcid":false,"given":"Jingjin","family":"Li","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Shariff","sequence":"additional","affiliation":[{"name":"Regeneron UK Ltd Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha","family":"Namuduri","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafia","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Unit\u00e0 Sanitaria Locale IRCCS of Reggio Emilia Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"17","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T\u2010cell engagement: current state of CAR T cells and bispecific antibodies in B\u2010cell lymphomas","volume":"8","author":"Haydu JE","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR\u2010HEMATOTOX risk\u2010stratifies patients for severe infections and disease progression after CD19 CAR\u2010T in R\/R LBCL","volume":"10","author":"Rejeski K","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"13","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta\u2010analysis","volume":"8","author":"Reynolds GK","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell\u2010associated haematotoxicity after CAR T\u2010cell therapy: from mechanism to management","volume":"11","author":"Rejeski K","year":"2024","journal-title":"Lancet Haematol"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omto.2022.10.006","article-title":"Cross\u2010study safety analysis of risk factors in CAR T cell clinical trials: an FDA database pilot project","volume":"27","author":"Foster M","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B\u2010cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi L","year":"2023","journal-title":"Blood"},{"issue":"24","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR\u2010HEMATOTOX: a model for CAR T\u2010cell\u2010related hematologic toxicity in relapsed\/refractory large B\u2010cell lymphoma","volume":"138","author":"Rejeski K","year":"2021","journal-title":"Blood"},{"issue":"10","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2010associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski K","year":"2023","journal-title":"Blood"},{"issue":"5","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20\u2010positive B\u2010cell malignancies (ELM\u20101): results from the relapsed or refractory non\u2010Hodgkin lymphoma cohort in a single\u2010arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji R","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim TM","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM\u20102 trial","volume":"6","author":"Kim WS","year":"2025","journal-title":"Nat Cancer"},{"issue":"14","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T\u2010cell therapy: primary analysis of the ELM\u20101 study","volume":"145","author":"Topp MS","year":"2025","journal-title":"Blood"},{"issue":"4","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn K","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL\u2010Hematotox: predicting post\u2010CAR T\u2010cell hematotoxicity in B\u2010cell acute lymphoblastic leukemia","volume":"145","author":"Nair MS","year":"2025","journal-title":"Blood"},{"issue":"20","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T\u2010cell expansion in a patient with bone marrow failure after CD19 CAR\u2010T therapy for Richter\u2010transformed DLBCL","volume":"140","author":"Rejeski K","year":"2022","journal-title":"Blood"},{"issue":"4","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B\u2010cell lymphoma","volume":"106","author":"Logue JM","year":"2021","journal-title":"Haematologica"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.544754","article-title":"Efficacy and safety of CAR\u2010modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta\u2010analysis of prospective clinical trials","volume":"11","author":"Xiang X","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","article-title":"Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19\u2010directed CAR T\u2010cell therapy \u2013 a case report","volume":"21","author":"Rejeski K","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR\u2010HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA\u2010directed CAR\u2010T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski K","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"11","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR\u2010HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski K","year":"2023","journal-title":"Am J Hematol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.19539","article-title":"Risk factors analysis and nomogram development for myelosuppression in diffuse large B\u2010cell lymphoma patients undergoing first\u2010line chemotherapy: a dual\u2010centre retrospective cohort study","volume":"13","author":"Wang X","year":"2025","journal-title":"PeerJ"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","article-title":"The multifaceted functions of neutrophils","volume":"9","author":"Mayadas TN","year":"2014","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"e_1_2_10_25_1","article-title":"Comparative effectiveness of odronextamab versus real\u2010world systemic therapies used in an external control arm in patients with relapsed\/refractory follicular lymphoma","volume":"9","author":"Bachy E","year":"2025","journal-title":"HemaSphere"},{"issue":"3","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100020","article-title":"Predicting infection risk following CAR\u2010T using the bedside CAR\u2010HEMATOTOX score: performance in an Australian cohort","volume":"1","author":"Reynolds GK","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"3","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70096_785","article-title":"Hematologic toxicity analysis of CAR\u2010T cell therapy: a retrospective real\u2010world study","volume":"43","author":"Wang H","year":"2025","journal-title":"Hematol Oncol"},{"issue":"4","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"240.e1","DOI":"10.1016\/j.jtct.2025.01.888","article-title":"Prospective validation of CAR\u2010HEMATOTOX and a simplified version predict survival in patients with large B\u2010cell lymphoma treated with anti\u2010CD19 CAR T\u2010cells: data from CART\u2010SIE study","volume":"31","author":"Stella F","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2024-209879","article-title":"Population\u2010based external validation of the CAR\u2010HEMATOTOX score to predict CAR T cell related toxicity and outcome in R\/R LBCL patients","volume":"144","author":"Boer JW","year":"2024","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:37:55Z","timestamp":1792625875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":28,"alternative-id":["10.1111\/bjh.70869"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70869","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70869"}}